Partnered with Adimab LLC for antibody development in dementia and Alzheimer’s disease (AD), Alector LLC raised an undisclosed amount of money in its Series A round, enough to last “two or three years, we think,” said CEO Arnon Rosenthal, who estimated “at least four years before we are in the clinic” with a drug that might succeed where so many others have not.
Help employers find you! Check out all the jobs and post your resume.
